Therapeutic expression of human clotting factors IX and X following adeno-associated viral vector-mediated intrauterine gene transfer in early-gestation fetal macaques by Chan, JKY et al.
THE
JOURNAL • RESEARCH • www.fasebj.org
Therapeutic expression of human clotting factors
IX and X following adeno-associated viral
vector–mediated intrauterine gene transfer
in early-gestation fetal macaques
Jerry K. Y. Chan,*,†,1 Irene Gil-Farina,‡ Nuryanti Johana,* Cecilia Rosales,§ Yi Wan Tan,* Jessika Ceiler,‡
Jenny Mcintosh,{ Bryan Ogden,k Simon N. Waddington,#,** Manfred Schmidt,§,†† Arijit Biswas,‡
Mahesh Choolani,{ Amit C. Nathwani,§ and Citra N. Z. Mattar{,2
*Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore, Singapore; †Cancer and Stem Cell Biology Program,
Duke–National University of Singapore (NUS) Medical School, Singapore; ‡Department of Translational Oncology, German Cancer Research
Center/National Center for Tumor Diseases, Heidelberg, Germany; §United College London (UCL) Cancer Institute and #Institute for Women’s
Health, University College London, London, United Kingdom; {Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore; kSingHealth Experimental Medicine Centre, Singapore Health Services Pte, Singapore, Singapore; **Faculty
of Health Sciences, Wits/South African Medical Research Council (SAMRC) Antiviral Gene Therapy Research Unit, University of the
Witwatersrand, Johannesburg, South Africa; and ††GeneWerk, Heidelberg, Germany
ABSTRACT:Adeno-associatedviralvectors(AAVs)achievestabletherapeuticexpressionwithoutlong-termtoxicityinadults
with hemophilia. To avert irreversible complications in congenital disorders producing early pathogenesis, safety and
efficacyofAAV-intrauterinegene transfer (IUGT) requires assessment.We thereforeperformed IUGTofAAV5or -8with
liver-specificpromoter-1 encodingeitherhumancoagulation factors IX (hFIX)orX (hFX) intoMacaca fascicularis fetusesat
∼0.4gestation.Theinitialcohortreceived13 1012vectorgenomes(vgs)ofAAV5-hFIX(n=5;0.453 1013vg/kgbirthweight),
resulting in∼3.0%hFIXat birth and0.6–6.8%over 19–51mo.Thenext cohort received0.2–13 1013 vgboluses.AAV5-hFX
animals (n=3;3.573 1013vg/kg)expressed<1%atbirthand9.4–27.9%upto42mo.AAV8-hFIXrecipients (n=3;2.563 1013
vg/kg) established 4.2–41.3% expression perinatally and 9.8–25.3% over 46 mo. Expression with AAV8-hFX (n = 6, 3.123
1013 vg/kg) increased from <1%perinatally to 9.8–13.4% >35mo. Low expressers (<1%, n = 3)were postnatally challenged
with 2 3 1011 vg/kg AAV5 resulting in 2.4–13.2% expression and demonstrating acquired tolerance. Linear
amplification–mediated-PCR analysis demonstrated random integration of 57–88% of AAV sequences retrieved from
hepatocytes with no events occurring in or near oncogenesis-associated genes. Thus, early-IUGT in macaques produces
sustained curative expression related significantly to integrated AAV in the absence of clinical toxicity, supporting its
therapeutic potential for early-onsetmonogenicdisorders.—Chan, J.K.Y.,Gil-Farina I., Johana,N.,Rosales,C., Tan,Y.W.,
Ceiler, J.,Mcintosh,J.,Ogden,B.,Waddington,S.N.,Schmidt,M.,Biswas,A.,Choolani,M.,Nathwani,A.C.,Mattar,C.N.Z.
Therapeutic expression of human clotting factors IX andX following adeno-associated viral vector–mediated intrauterine
gene transfer in early-gestation fetal macaques. FASEB J. 33, 3954–3967 (2019). www.fasebj.org
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Clinical gene therapy (GT) trials for severe mono-
genic diseases have demonstrated survival benefit over
existing therapies. In recent phase I trials for hemophilia,
adeno-associated viral vectors (AAVs)-GT achieved dose-
dependent hematologic correction, with reassuring
safety profiles (1, 2). Nevertheless, ongoing hemarthrosis
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site; IUGT, intrauterine gene transfer; LAM, linear amplification–mediated; LP, liver-specific promoter; MNC, mononuclear cell; NAb, neutralized antibody;
NHP, nonhuman primate; scAAV, self-complementary AAV; US, ultrasound; VC, vector challenge; VCN, vector copy number; vg, vector genome
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in adults limits phenotype correction despite efficient
transduction (3, 4). Early AAV-GT preceding permanent
tissue damage is thus an attractive prospect for chil-
dren with monogenic conditions (3–6). Infants with spi-
nal muscular atrophy treated with self-complementary
AAV (scAAV)9.CB.hSMN demonstrated significant
dose-dependent neurologic improvement and higher
unventilated survival when comparedwith controls (7).
The most beneficial application of GT may be during
early fetal development, particularly for syndromes
that manifest in utero and in which postnatal thera-
peutic potential is limited by irreversible tissue dam-
age or inefficient protein replacement (8–10), examples
of which include neuronopathic Gaucher disease and
other neurometabolic syndromes (11–13) and congeni-
tal factor X (hFX) deficiency, which causes perinatally
lethal intracranial hemorrhage (14–16). In such condi-
tions, better outcomes are demonstrated when genetic
correction is attempted in utero rather than in later
childhood, and improving accuracy of early prenatal
testing is likely to drive the demand for fetal therapies
(6, 17–22).
Clinical outcomes depend on fetal maturity status at
intervention (23). Increased fetal stem cell receptivity to
vector transduction (24–26), minimal pre-existing tissue
damage (27, 28), and immune naı¨vete´ facilitating vector
tolerance (20, 29–31) increase the likelihood of long-term
phenotype correction. It is, however, critical to interrogate
organ- and genotoxicity in addition to protein deficiency
correction in GT applications—issues that have arisen in
the successful gene transfer of young children with severe
congenital immunodeficiency and spinal muscular atro-
phy (7, 32). Most intrauterine gene transfer (IUGT) animal
models do not demonstrate the degree of transgenic pro-
tein production the we have described in nonhuman pri-
mates (NHPs), here and previously (29, 33). Murine IUGT
with AAV1-human factor IV (hFIX) or AAV2-hFIX at
1012–1013 vector genomes (vgs)/kg showedpersistent low
transgene levels, requiring AAV readministration for
therapeutic expression (31). Ovine AAV-IUGT produced
only low expression up to 6 mo after peak expression at
;3wkafter injection (34).NHP-IUGTwith scAAV5- liver-
specific promoter (LP)-1-hFVII maintained;20% expres-
sion at birth, successfully boosted, after loss of expression,
by the alternate AAV8 serotype, which thereafter sup-
ported therapeutic FVII levels without a sustained im-
mune response (35).Despite the expandingapplicabilityof
recombinant AAV pseudotypes engineered for improved
safety via specific organ targeting and reduced insertional
oncogenesis, a major limitation is its predominantly epi-
somal nature (36–42). These animal studies demonstrate
the progressive loss of expression expected after fetal or
neonatal treatment as the recipient grows (43). In-
troduction of GT vectors during fetal development to
induce immune tolerance and facilitate repeat AAV ad-
ministration after birth (33, 44–46) can be a useful strategy
for stabilizing waning protein expression in the hemo-
philias and neurometabolic disorders (11, 47). Despite the
encouraging outcomes of clinical trials, high-dose AAV
has resulted in complications associated with integration,
direct cellular toxicity, and systemic inflammation, resulting
in hepatocellular carcinoma in rodents, neurodegeneration
in piglets and liver failure in juvenile NHPs (48, 49). Data
regarding AAV-IUGT safety and efficacy can thus originate
only from a high-fidelity NHPmodel in which longitudinal
surveillance is clinically relevant (50). We have described
long-term outcomes of liver-directed late-gestation IUGT in
NHPbyusing the clinical vector scAAV-LP1-human codon-
optimizedhumanFIX transgene (FIXco) (5) inwhicha single
injection at 0.9 gestation demonstrated therapeutic hFIX ex-
pression in most animals (29, 33). Low-expressing animals
were safely boosted with only transient immune responses
(33).UsinghFXasamarker transgene in the samemanner as
hFIX, we interrogated the expression, immune re-
sponse, and vector biodistribution after single-dose
early-IUGT at ;0.35–0.4 gestation in an established
NHP model in which we used AAV5 and -8 vectors
expressing either hFIX or hFX codon-optimized trans-
genes (50). This study is the first that we know of to
describe in extensive detail the clinically relevant out-
comes of early IUGT in a large number of NHPs. We
report unexpectedly prolonged and stable postnatal
transgenic protein production with only transient
transaminitis, a high level of vector integration with no
hotspots, and evidence of immune tolerance.
MATERIALS AND METHODS
Vector production
scAAV-LP1-hFIXco was produced as described by Nathwani
et al. (44). scAAV-LP1-hFXco was produced similarly, replacing
the hFIXco with the codon-optimized hFX transgene (hFXco),
from pAV-LP1-hFX with a truncated poly-A. AAV-inverted
terminal repeats with the LP1 promoter were cut with HindIII/
MfeI, ligatedwithT4DNAligase (NewEnglandBiolabs, Ipswich,
MA, USA), and heat shocked into competent Escherichia coli,
which were grown at 37°C overnight (51). Correct clones were
identified after DNA extraction by digestion with HindIII/PstI,
AhdI, and BglI. Plasmid expression of hFX expression was
assessed by ELISA after transient transfection of HepG2 cells
with Fugene (Roche, Basel, Switzerland), and clones were am-
plified with Megaprep (Qiagen, Limberg, The Netherlands).
scAAV-LP1-hFIXco and scAAV-LP1-hFXco plasmids were used
in adenovirus-free transient transfection of 293T cells to generate
scAAV5 and scAAV8 pseudotypes, as described by Nakai et al.
(45). Titerswere determined by quantitative PCRwith linearized
plasmids used as standards.
IUGT, fetal blood sampling, delivery
and monitoring
All procedures were performed inMacaca fascicularis strictly ad-
hering to recommendations from the Institutional Animal Care
and Use Committee at the National University of Singapore and
Singapore Health Services Pte, Ltd. (IACUC 2012/SHS/692).
The in vivowork was conducted at the SingHealth Experimental
Medicine Centre (SEMC, Singapore), accredited by the Associa-
tion for Assessment and Accreditation of Laboratory Animal
Care International. Timedmating andpregnancymonitoring are
described in refs. 29 and 50. Vector was administered to ma-
caques under ketamine sedation via intraperitoneal, intracardiac,
or intravascular injection with an 18-gauge Quincke spinal nee-
dle (BD Biosciences, Franklin Lakes, NJ, USA) with ultrasound
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(US) guidance (Table 1). Injected volumes were restricted to
500ml, and fetal heart ratewasmonitored for5minafter injection.
Routine maternal and fetal surveillance, fetal blood sampling
(FBS) at;0.6G, caesareandelivery, and infanthand-rearingwere
performed (50). From1yrof age,hepatic andother tissuebiopsies
were performed at 6-mo intervals to assess vector biodistribution
and integration (29).
Postnatal vector challenge
Three infants with postnatal transgenic protein production of
,1% were prepared for and serially monitored after vector
challenge (VC), as previously described (33). Each received
2 3 1011 vg/kg body weight of AAV-hFIX or AAV-hFX and
were monitored for immediate adverse reactions (Fig. 1).
Treated subjects underwent open or percutaneous US-guided
liver biopsies (Tru-Cut Needle; CareFusion, Basingstoke,
United Kingdom) 3 mo after VC to assess vector load, hepa-
totoxicity, and vector integration. Wedge biopsies were col-
lected via upper abdominal midline incision with hemostasis
(50). All procedureswere performed under ketamine sedation
(IUGT, FBS, and VC) or general anesthesia (caesarean de-
livery, liver biopsy).
Transgenic protein production
hFIX was analyzed by quantitative ELISA, as previously
described (29). hFXwas analyzed by using the same protocol
with FX-EIA-C capture antibodies and FX-EIA-D detecting
antibodies (Matched-Pair Antibody Set for ELISA of human
factor X antigen, Affinity Biologicals, Ancaster, ON, Can-
ada). Serum samples from injected offspring were diluted at
1:50 and 1:100 in HEPES-buffered saline-bovine serum al-
bumin (BSA)-Tween 20 sample diluent for analysis. Human
FX protein (ab62549; Abcam, Cambridge, United Kingdom)
reconstituted in naive NHP serum and diluted serially from
0.075 to 10 mg/ml (0.75–100%) in HEPES-buffered saline-
bovine serum albumin (BSA)-Tween 20 served as refer-
ence standards. Colorimetric change was developed and
analyzed.
Liver-specific expression
Liver-specific expression of hFIX and hFX was determined by
RT-PCR, as previously described (29). The resultant cDNA (2ml)
was used to amplify a 617-bp region of the hFIX transgene with
the forward 59-TTTCCTGATGTGGACTATGT-39 and reverse
59-TCATGGAAGCCAGCACAGAACATG-39 primers. The hFX
transgene was amplified with the human-specific forward
59-GAGAGGGGCGACAACAACCTCAC-39 and reverse 59-AG-
GCATCCTCCTGCTTGGTGTCG-39 primers, producing a 568-bp
amplicon. cDNA integrity was determined by amplifying a
604-bp region of the macaque b-actin gene by using forward
59-TGACGGGGTCACCCACACTGTGCCCATCTA-39 and re-
verse 59-CTAGAAGCATTTGCGGTGGACGATGGAGGG-39
primers. Cycling conditions were: 95°C for 5 min, 40 cycles of
95°C for 30 s, 57°C for 30 s (hFIX), or 60°C for 30 s (hFX, b-actin)
and 72°C for 60 s,with final extension of 72°C for 7min,with the
product resolved on 2% agarose gel.
Viremia and vector biodistribution
Assessment of viremia and vector biodistributionwere performed
as previously described for both hFIX and hFX-treated animals
(29). In brief, 5 ml of cell-free maternal plasma or 15 mg genomic
DNA extracted from tissue was amplified for an 84-bp region of
the transgene encompassing the 39 end of the codon-optimized
transgene and the 59 region of the SV40 late poly A sequence with
100 nM each of forward 59-GGGCAAGTATGGCATCTACA-39
and reverse 59-AAAGCATCGAGTCAGGTCAG-39 primers. Viral
load was expressed as copies per microliter maternal plasma
(viremia) or vector copy number (VCN) per diploid genome
(6.6 pg of DNA); the calculated limit of detection was 1 vg
per 455 diploid genomes. Equivalent loading was assessed by
amplifying a 52-bp region of the macaque b-actin gene with for-
ward 59-TCCTGTGGCATCCACGAAA-39 and reverse 59-CCA-
CGTCACACTTCATGATGG-39 primers.
Anti-AAV binding and neutralizing antibodies
Binding anti-capsid antibodies were assessed by sandwich
ELISA, as previously described (29), using 5 3 108 AAV8 or
TABLE 1. Biodata and outcomes of fetuses injected in early gestation with scAAV-LP1-hFIXco and scAAV-LP1-hFXco
Infant Gender AAV
Gestation
at IUGT (d)
Total
dose (vg)
Dose in
vg/kg
Route of
delivery
Gestation
at birth (d)
Birth
weight (g) Outcome (mo)
Factor IX
e5001 Male AAV5 0.35 (54) 1 3 1012 6 3 1012 IP 144 165 Stillborna
e5002 Female AAV5 0.36 (56) 1 3 1012 4.26 3 1012 IP 147 235 Alive (19)
e5003 Male AAV5 0.37 (58) 1 3 1012 3.64 3 1012 IP 147 275 Alive (19)
e5004 Male AAV5 0.45 (69) 1 3 1012 4.35 3 1012 IC 146 230 Deceased (1)b
e5005 Male AAV5 0.46 (71) 1 3 1012 4.08 3 1012 IH 146 245 Alive (65)
e8001 Male AAV8 0.46 (71) 0.2 3 1013 6.90 3 1012 IP 148 290 Alive (62)
e8002 Male AAV8 0.61 (94) 1 3 1013 3.23 3 1013 IH 149 310 Alive (62)
e8003 Male AAV8 0.48 (75) 1 3 1013 3.77 3 1013 IP 145 265 Alive (62)
Factor X
e5001FX Female AAV5 0.48 (75) 1 3 1013 3.28 3 1013 IP 149 305 Alive (14)
e5002FX Female AAV5 0.37 (58) 1 3 1013 3.70 3 1013 IP 147 270 Alive (58)
e5004FX Female AAV5 0.47 (74) 1 3 1013 3.73 3 1013 IH 149 300 Deceased (15)c
e8001FX Unknown AAV8 0.31 (48) 1 3 1013 NA IP N.A. N.A. Miscarried
e8002FX Unknown AAV8 0.37 (57) 0.5 3 1013 NA IP N.A. N.A. Miscarried
e8003FX Female AAV8 0.37 (58) 1 3 1013 3.39 3 1013 IP 147 295 Alive (57)
e8004FX Unknown AAV8 0.38 (59) 1 3 1013 NA IP N.A. N.A. Miscarried
e8005FX Female AAV8 0.37 (57) 1 3 1013 2.74 3 1013 IP 149 365 Alive (52)a
e8006FX Male AAV8 0.35 (55) 1 3 1013 3.22 3 1013 IP 147 310 Alive (44)a
aFBS performed at 0.6 gestation. bDied of sepsis. cUnknown cause of death.
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AAV5 particles as coating antigens, samples diluted 1:49 and
goat anti-rhesus IgG (1:3999dilution). Resultswere standardized
to the negative baseline (readout of samples from unexposed
macaques) and expressed as a ratio of the positive control
(readout from a sensitized adult macaque strongly positive for
anti-AAV8 or -5) (44). Neutralizing antibodies (NAbs) were
assessed in vitro by incubating samples diluted 1:99with 53 1010
AAV5 or -8 particles and then with 1 3 105 293T cells, as de-
scribed in refs. 29 and 52. At least a 50% reduction in GFP
transduction, relative to the control, was indicative of NAbs.
Control subjects were immune-competent, unexposed, adult
male macaques capable of producing anti-AAV antibodies as a
primary response, which did not produce NAb during the first
month after exposure.
Cell-mediated immunity
Cell-mediated reactions to postnatal VC were analyzed by in-
tracellular staining (ICS) adapted froma published protocol (53),
as previously described (33). All antibodies and reagents were
acquired from BD Biosciences unless stated otherwise. Briefly,
frozenperipheralbloodmononuclear cells (MNCs)were thawed,
Figure 1. Individual hFIX and hFX expression in treated animals. A–C) Animals treated with AAV5-hFIX and monitored beyond
infancy were e5002FIX (A) and e5003FIX (B), both of which showed subtherapeutic levels, and e5005FIX (C), which
demonstrated therapeutic levels. (D–F) expression in e5001FX (D), e5002FX (E), and e5004FX (F) ﬂuctuated between
subtherapeutic (,1%) and high levels, whereas infant body mass steadily increased; e5004FX showed the more stable expression
overall. G–I) AAV8 recipients were e8001FIX (G), e8002FIX (H), and e8003FIX (I), which sustained hFIX expression .1%
(100% = 5 mg/ml) despite rapid growth. J–L) e8003FX (J ), e8005FX (K), and e8006FX (L) fared similarly with median hFX
expression in the therapeutic range (100% = 10 mg/ml). Arrows: postnatal VC.
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incubated overnight in Rosewell Park Memorial Institute
(RPMI) 1640 with 10% fetal bovine serum and 1% penicillin/
streptomycin at 37°C in 5% CO2, washed with HBSS supple-
mented with 2 U/ml DNase I, and resuspended in RPMI 1640.
MNCswere first stimulated in the presence of either anAAV8 or
-5 capsidpeptidepool (final concentration, 2.5mgperpeptideper
milliliter) in the presence of anti-CD28 (clone CD28.2), anti-
CD49d (clone 9F10), and Brefeldin A. Nonviable and non-T cells
were gated out with the Live/Dead Fixable Violet Dead Cell
Stain Kit-Pacific Blue (Thermo Fisher Scientific, Waltham, MA,
USA); anti-CD14-Pacific Blue (cloneM5E2), anti-CD16-Pacific
Blue (clone 3G8), and anti-CD20-Pacific Blue (clone 2H7; Bio-
Rad, Oxford, United Kingdom); and T-cell subtypes were
determined analyzedwith anti-CD8-APC-H7 (clone SK1) and
anti-CD4-Alexa700 (clone OKT4; eBioscience, San Diego, CA,
USA); anti-CD95-PE-Cy5 (clone DX2) and anti-CD28-PE-
Texas Red (clone CD28.2; Beckman Coulter, Brea, CA, USA);
and anti-CCR7-PE (clone 150503; R&D Systems,Minneapolis,
MN, USA) for 30 min at 4°C in the dark. After permeabilizing
with Cytofix/Cytoperm for 20 min at room temperature, ICS
was performed with anti-IFN-g-APC (clone B27), anti-IL-2-
FITC (clone MQ1-17H12), anti-TNF-a-PE-Cy7 (clone MAb11)
and anti-CD3-PerCP-Cy5.5 for 30min at 4°C in the dark. Fixed
cellswere analyzed by fluorescence-activated cell sortingwith
LSR Fortessa and FACSDiva software (BD Biosciences).
Postacquisition analyses were performed with Summit 4.2
(Beckman Coulter). Single-color controls were added via
Compbeads Anti-Mouse Ig, k (BD Biosciences). Cells were
gated onto CD3 and then onto CD8 or CD4 cells, which in turn
were gated onto CD95 and CD28, to differentiate effector and
memory cells, as previously described (33). Effector and
memory cellswere gated onto cytokines IL-2, IFN-g, andTNF-
a. Naive macaque MNCs incubated in phorbol 12-myristate
13-acetate and ionomycin (5 mg/ml) served as the positive
control; the negative control consisted of MNCs incubated in
peptide-freemedium. Samples were read as positive if at least
0.05% of a subpopulation stained for a particular cytokine.
Integration sites analyses by linear
amplification–mediated-PCR and
high-throughput sequencing
Linear-amplification–mediated (LAM) PCR was performed as
described in refs. 29, 33, and 54. In brief, AAV flanking sequences
frombothAAV-hFIXandAAV-hFXvectorswereamplified from
750 ng genomic DNA from liver biopsies by using the same
primers (Supplemental Table S1). Restriction digest steps were
performed with the MseI and MluCI restriction enzymes (New
England Biolabs). After 1 linear and 2 exponential PCRs, an ad-
ditional PCR amplification with barcoded fusion primers was
performed to prepare fragments for 250PE MiSeq sequencing
(Illumina, San Diego, CA, USA). Raw sequences were ana-
lyzed by automated bioinformatics tools for quality filter,
vector trimming, and identification of vgs [integration sites
(ISs)] and vector-vector (concatemers) junctions. ISs were
mapped to the macaque genome by using the University of
California at Santa Cruz Blast-like alignment tool and were
analyzed by automated data-mining tools to characterize the
vector’s integration profile (55).
Statistics
Results were analyzed using statistical software Prism v.6.04
(GraphPad Software, La Jolla, CA, USA). Data are shown as
means 6 SD, and analyzed using unpaired Student’s t tests. A
value of P , 0.05 was considered significant. Frequency of in-
tegration sequence retrieval from tissue samples of subjects was
compared by Fisher’s exact test.
RESULTS
Monitoring and survival of treated animals
Fourgroupsof fetuseswere treated: scAAV-LP1 serotypes
5 and 8, expressing either hFIX (5 mg/ml represents 100%
normal levels) or hFX (10 mg/ml represents 100% normal
levels) transgenes. Pregnant damswere assigned treatment
groups based on anti-AAV5/8 seronegativity. AAV-hFIX
IUGT (AAV5, n = 5; AAV8, n = 3) was performed at 48–94
gestational days (GDs) or 0.31–0.61 gestation (median,
0.37 G) (Table 1). Routes of injection were determined by
fetal intrahepatic vein accessibility: 3 fetuses were injected
intravenously or intracardially [using a technique similar to
that employed in clinical fetal therapy of tachyarrhythmias
(56)], and the remainder were injected intraperitoneally or
intrahepatically. FBS was successfully performed in the
e5001, whichwas stillborn at 144 GDs (0.9 G; Table 1). Fetal
viability was confirmed by US. The first 5 fetuses (e5001,
e5002, e5003, e5004, and e5005) received 1 3 1012 vg of
AAV5-hFIXco to assess expression at a deliberately low
starting dose and avoid potential toxic inflammatory reac-
tions fromvector overload. Interimanalysis of e5001 by FBS
(0.6 gestation) demonstrated hFIX levels of 1.7%. Higher
dosesof0.231013vg (n=1)and131013vg (n=2)ofAAV8-
hFIX were used thereafter to improve expression. AAV-FX
animals received 1 3 1013 vg of scAAV-LP1-hFXco IP at
48-75GDs (0.31–0.48 gestation; AAV8, n = 6; AAV5, n = 3;
Table 1). e8002FX received 0.53 1013 vg of available vector
stocks (volumes restricted to 500ml). FBSwas performed at
83–99 GDs (0.54–0.64 gestation; n = 3). Animal loss from
procedural technicalities occurred at a rate comparable to
late IUGT (33). Infants were delivered at 144–149 GDs at
median birth-weight of 275 g (range, 165–365 g) (50). They
developed normally except for e5004, which perished from
nosocomial pneumonia at 5 wk of age (Table 1).
Dose-dependent transgenic protein
production according to serotypes 5 and 8
AAV5-hFIX animals (1 female, 4 males) received a mean
doseof 0.453 1013 vg/kg calculatedbybirthweight. Early
hFIX expression ranged from 4.2% (e5001 at 0.6 gestation)
to 3.0 6 1.8% (e5001 at 0.9 gestation, stillbirth) and 4.9%
(e5004, perimortem at 1 mo of age). Steady-state expres-
sion ranged from low levels of ;0.6 6 0.8% (e5002 and
e5003) over;19moand5–6-foldweight gain (Fig. 1A,B) to
6.8 6 3.8% (e5005) over ;51 mo and 10-fold weight gain
(Fig. 1C; P, 0.0001). Both e5002 and e5003 expressed,1%
ofnormal levelsat1yrandunderwentpostnatalVC.AAV5-
hFXanimals (3 females) received ameandose of 3.573 1013
vg/kg. hFX levels reached 0.4–0.7% at birth (e5001FX and
e5002FX) and ranged from 27.96 10.8% (;9 mo, e5004FX)
to 9.46 10.0% (;42 mo, e5002FX) after IUGT with weight
gains of 4–8-fold (Fig. 1D–F). AAV8-hFIX–treated animals
(3 males) receiving a mean dose of 2.56 3 1013 vg/kg
showed expression of 1.6%at 0.6 gestation (30 d after IUGT,
e8003) and between 4.2% (e8001) and 41.3% (e8002) at birth.
Surveillance over;46moafter IUGTdemonstratedplateau
levels from 9.86 5.2% (e8003) to 25.36 11.1% (e8001) with
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an8–11-foldweightgain (Fig.1G–I).hFX levelswere,1%at
0.6 gestation (e8005FX and e8006FX by FBS) and at birth
(e8003FX) among AAV8-hFX recipients given 3.12 3 1013
vg/kg. This level increased to steady-state mean levels be-
tween 9.86 7.8% and 13.46 10.3% over 31–35 mo, with a
6–9-fold weight gain (Fig. 1J–L). Mean hFIX levels from
AAV5 animals that had received the lower vector dose of
0.53 1013 vg/kg (basedon eventual birthweight),was lower
over65mothan inAAV8infantsafter2.631013vg/kg(5.66
4.1% vs. 17.76 5.7%; Fig. 2A). hFX expression observed over
50 mo was similar between AAV8 and -5 recipients which
had received doses of 3.1–3.6 3 1013 vg/kg (9.8 6 6.6% vs.
12.9 6 10.3%, Fig. 2B). In AAV8 animals receiving vector
doses of 2.6–3.1 3 1013 vg/kg, higher levels of hFIX were
observed than hFX (19.3 6 8.0% vs. 9.8 6 6.6%, Fig. 2C).
AAV5 animals showed dose-dependent transgenic protein
levels of 12.96 10.3% hFX at a dose of 3.63 1013 vg/kg and
6.36 4.1% hFIX after a dose of 0.53 1013 vg/kg (Fig. 2D).
Immune responses to vector administration
in IUGT recipients
Infants receiving either serotype demonstrated similar hu-
moral responses to capsid and transgenic proteins. Persis-
tent anti-capsid IgG antibodies were observed from 0.6
gestation throughout the surveillance period and remained
below the positive threshold (Fig. 3A). Responses to both
transgenes were subdued (Fig. 3B, C). Maternal anti-AAV5
antibody expression wasmore robust than anti-AAV8 (Fig.
3D) and anti-transgene responses were mild (Fig. 3E) (29).
Transgenic protein production and immune
response after postnatal VC
e5002, e5003, and e5002FX were negative for binding
and neutralizing anti-AAV antibodies and had normal
transaminases, hematologic indices, and liver histology
before VC (Fig. 4). None developed acute post-VC in-
flammatory responses over 90 d of monitoring. e5002
(3.2 3 1011 vg) showed transient hFIX elevation at 8 and
24 d after VC (peak, 2.46 3.3%; overall mean, 0.86 0.8%),
whereas in e5003 (2.73 1011 vg) hFIX showed immediate
improvement until;25 d (peak 7.76 8.6%, overall 1.36
2.0%). e5002FX (2.1 3 1011 vg) expressed ,1% hFX until
27 d after VC, subsequently peaking at 13.2 6 3.6% at
30 d (overall, 4.2 6 6.4%). Transgene levels are summa-
rized in Fig. 5A. Anti-AAV IgG antibodies remained be-
low the positive threshold in e5002 and e5003 and were
largely undetectable in e5002FX (Fig. 5B). No IgG pro-
duction against hFIX or hFXwas observed. Only e5002FX
producedNAbs from7 to21dafterVC,before a resolution
that preceded the increase in hFX expression (Fig. 5C, VC
at d 0). NAbs were not demonstrated in e5002 and e5003.
e5002 showed a.300-fold increase in hepatic VCN (from
0.01 to 2.00 copies/cell), whereas the VCN in e5003
remained at 0.10 copies/cell. Hepatic VCN in e5002FX
decreased from0.4 to 0.006 copies/cell (Fig. 5D).Activated
CD4 and CD8 T-cells expressing TNF-a and IFN-g were
observed against AAV5 capsid proteins (Fig. 5E). e5002FX
showed increasing activated T cells from first to second
postnatal VC, diminishing over the following 3 wk. Both
e5002 and e5003 showed higher activated CD4 and CD8
T cells, decreasing over 4 wk. Both e5002 and e5003 peri-
shed from anesthesia-related complications following
liver biopsies at 30 d after VC (Fig. 1).
Biosafety: vector biodistribution and
integration analysis
Transduction was analyzed via serial biopsies of liver,
omentum, skin, fat, and muscle from the neonatal period
in e5001 (stillbirth, ;80 d after IUGT), in e5004 at 5 wk
Figure 2. Serotype-dependent
hFIX and hFX expression. A)
AAV5 animals produced lower
hFIX levels (5.6 6 4.1% after
0.5 3 1013 vg/kg) than AAV8
infants (17.7 6 5.7 after 2.6 3
1013 vg/kg). B) hFX expression
was similar in AAV8 (9.86 6.6%)
and AAV5 animals (12.9 6
10.3%) which received similar
doses. C) AAV8 produced higher
levels of hFIX (19.3 6 8.0%)
than hFX (9.8 6 6.6%) at simi-
lar vector doses. D) AAV5 showed
dose-dependent production of
hFX (12.9 6 10.3% after a dose
of 3.6 3 1013 vg/kg) compared
to hFIX (6.36 4.1% after 0.53
1013 vg/kg).
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(;120 d), and from 12 to 42 mo in surviving offspring.
Mean VCN ranged from 0.002 6 0.001 copies/cell (cere-
brum) to 6.7 6 11.1 copies/cell (skin); hepatic VCN was
0.36 0.1 copies/cell, and therewas no demonstrable liver
tropism (Fig. 6A). We observed time-dependent log-fold
decreases in VCN during each 12-mo period (1–36m; P,
0.05). VCN in skin and muscle (highest starting vector
load) decreased ;2–3-log-fold by 42 mo (Fig. 6B). The
decrease inVCN is shown in the context of sustained hFIX
and hFX levels, as expression per hepatic VCN increased
with time (Supplemental Fig. S1A). Liver-specific alanine
transaminase (ALT) levels were generally normal, al-
though it was increased at one time point in the AAV5
group (20 mo, 4–6 mo after VC; Fig. 6C). Aspartate trans-
aminase levels were above the upper limit for the first 20
mo before decreasing; a trend toward higher levels was
observedwithAAV5(SupplementalFig. S1B).Despite this
biochemical transaminitis, leukocyte counts and other
hematologic indices registered only mild fluctuations
within the upper normal limit, and there was no clinical
evidence of hepatotoxicity (e.g., anorexia, weight loss).
Liver histology 3 mo before and after postnatal challenge
did not demonstrate inflammatory cell infiltrates and
showednormalhepatocellulararchitecture (Supplemental
Fig. S1C, D).
Our previous data in late-IUGT NHP demonstrated
that integrated vector genome (;10%of sequences at 2–10
moafter birth), rather than concatemers, accounted for the
majority of vector persistence at later time points
(87.4–100% at 18–49 mo after birth) (33). In the present
study, LAM-PCR analyses revealed that 43.9–73.7% of
vector sequences were integrated at 10 mo, increasing to
87.5% at 42 mo (Fig. 7A). Amplicons obtained by LAM-
PCR yielded 4,217,447 raw reads, enabling identification
of 121 ISs corresponding to 111 unique and 14 multiple
mappable ISs (Table 2 and Fig. 7A). In e5002, the in-
tegratedvector accounted for 57.1%of retrieved sequences
3mo after VC (19moof age). Integration frequencieswere
Figure 3. Humoral response to
AAV capsid and transgenic pro-
tein. A) Anti-AAV binding anti-
bodies remained below the
positive threshold, and responses
were similar to AAV8 and -5. B)
Anti-hFIX antibodies remained
in the negative range with no
antibody production through
a large part of the surveillance
period. C) Anti-hFX antibody re-
sponse remained negative. D, E)
Maternal anti-AAV (D) and anti-
transgene (E ) responses were
subdued overall.
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similar in both groups (72.3 6 21.5% AAV5 vs. 58.8 6
21.1% AAV8; P = 0.6; Fig. 7B, C). We performed semi-
quantitative estimation of the sample clonal size by ana-
lyzing the 10 most frequently retrieved clones from the
different samples (Fig. 7D–F). Only two of these corre-
sponded to integration events in or near cancer-related
genes RAD23B and RAB1A (refer to the retroviral tagged
cancer gene databases: the Cancer Genomics Consortium,
https://www.cancergenomics.org/, and the cBio Portal for
Cancer Genomics, http://www.cbioportal.org/), and none
was retrieved at consecutive time points in the same
animal or from different animals. Considering all in-
tegration events identified, 7.2% of integration events
were located within or near cancer-related genes, which
did not significantly differ from the 8.9% found in a
synthetic random dataset. No significant targeting of
chromosomes or gene coding regions were identified
(Supplemental Fig. S1E, F), and there were no integration
events retrieved from the genomic regions previously re-
ported to be involved in AAV-associated oncogenesis (48).
DISCUSSION
Recent AAV-GT hemophilia trials have demonstrated
marked improvements in hemostatic stability and signif-
icantly reduced factor use in adults (3, 4, 57). Our data
affirm the ability of early AAV-IUGT to generate curative
expression of hFX and hFIX, stable for .4 yr, despite a
several-fold weight increase (signifying hepatic growth),
primarily represented by highly divergent and genome-
wide vector integration within genes and introns in equal
measure without demonstrable hotspots. No conclusions
canbedrawnas to the impact of administration route, as the
numbers are too small for comparison. We anticipate that
the intravenous route is the most efficient (58), but it results
in longerprocedures,potentiallygreater fetal stressor injury,
and more prolonged exposure to anesthesia than intraper-
itoneal injections (unpublished results). Administration and
surveillance strategies used for early and late IUGT were
intentionally similar, as all procedures are clinically appli-
cable and resulted in therapeutic expression levels for he-
mophilia B. Although the hemophilias are not conditions
that require in utero rescue from the perspective of disease
onset, it is encouraging that liver-directed AAV-driven GT
can be performed at 0.4 gestation with a reasonable expec-
tation of efficacy, safety, and technical feasibility. Substitut-
ing the relevant transgene for an inborn error ofmetabolism
orother similar condition intoAAV5or -8 canbeexpected to
effectively rescue a disease causing early fetal damage, the
most cogent argument for early IUGT.
Our data suggest that vector integration has a similarly
substantial and durable influence on stable long-term ex-
pression after both early and late IUGT, considering the
low percentage of remaining episomes in both 0.4 and 0.9
gestation animals by 42–47 mo (33). It is not possible to
Figure 4. Vector challenge protocol. All subjects selected for postnatal VC were screened for anti-AAV binding (Ab) and NAbs
underwent a prechallenge liver biopsy and were given 2 3 1011 vg/kg intravenously. All animals tolerated the additional dose of
vector with no clinically overt immunologic responses. e5002 and e5003 died from anesthetic complications during the
postchallenge liver biopsies.
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conclude at the present time whether this finding repre-
sents a translational advantage or risk in the longer term,
although the biosafety data would suggest low overall
integration-related risk. Our previous work showed that
AAV8 is the more efficient pseudotype for liver-directed
GT in 0.9 gestation fetal and adult macaques (29, 33, 59).
However, with IUGT at 0.4 gestation, AAV8 and -5 dem-
onstrate equivalence in their efficacies as seen by their
comparable hFX expression; lower expression among
AAV5-hFIX recipients was largely related to the log-fold
lowerdoseused, given that thenumberofmaleswas similar
in both groups. This finding demonstrates the utility of both
AAV8 and -5 for liver-directed early-IUGT strategies for a
range of congenital monogenic conditions with optimized
transgenes. From comparative studies of AAV8-GT in in-
fant and juvenile rodents and NHPs, clear correlation
is observed between age at treatment and hepatocyte
transducibility: earlier AAV8-GT produces higher, but ul-
timatelymore unstable, transduction caused by rapid liver
growth and episomal loss within 1–3 mo of vector deliv-
ery, with expression typically reaching a plateau (60, 61).
Hepatocyte transduction is also dose- and serotype-
dependent, as demonstrated by greater expression with
AAV8 (90–100% transduction) than with AAV2 (5–10%
transduction) (62–64) and the linear dose-response re-
lationship observed in adult macaques given 1010–1012
vg/kg of AAV8-hFIX (59).
Given these observations we had anticipated greater
transgenic protein production with early-IUGT than was
eventually achieved. The initial supraphysiological ex-
pression observed at 0.9 gestation was not seen at 0.4
gestation, which probably reflects superior episomal loss
from rapid intrauterine growth of early-IUGT recipients,
although median birth weights were comparable in both
Figure 5. Postnatal VC and re-
sponse. A) Three animals, e5002,
e5003 (both AAV5-hFIX), and
e5002FX (AAV5-hFX) received
2 3 1011 vg/kg AAV5. Trans-
gene levels were ,1% before
VC (d 0). Brief improvements
in expression were observed in
e5003 after VC and were sus-
tained over 23 d before being
nulliﬁed. e5002 showed short
spikes .1% at 8 and 24 d after
VC, whereas e5002FXmaintained
,1% hFX until an increase was
seen from d 27 after VC. B) Anti-
AAV IgG antibodies increased
mildly only in e5002 and e5003;
no such reaction was observed in
e5002FX, where anti-AAV5 IgG
was undetectable. No IgG pro-
duction against or was observed.
C) The presence of NAbs was de-
termined by loss of green ﬂuo-
rescent protein transduction to
#50% of baseline transduction
(normalized to 100%). e5002FX
demonstrated NAbs from d 7 to
21 after VC before resolution. D)
Pre- and postchallenge hepatic
VCN showed various responses
e5002 showed an increase from
0.01 to 2.00 copies/cell, whereas
VCN in e5003 remained at 0.10
vector/cell. No further follow-up
was possible, given that both re-
cipients died at the postchallenge
biopsy. A substantial decline from
0.35 to 0.01 copies/cell was ob-
served in e5002FX. E) e5002FX
showed an increase in activated
CD4 and CD8 T cells producing
TNF-a and IFN-g from ﬁrst to
second postnatal VC, but this
response quickly diminished by
3 wk after VC. Both e5002 and
e5003 showed higher activated
CD4 and CD8 T cells after VC,
which similarly decreased over
the following 4 wk.
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early and late-IUGT cohorts [275 vs. 267.5 g (range 205–
290 g)] (33). InNHPpregnancies harvested at 0.5 gestation
(median, 77.5GDs; range; 71–83d;n=10), themedian fetal
weight was 46.0 g (36.2–72.0 g) and livers weighed;1.9 g
(1.6–4.1 g; unpublished results). Using this fetal weight as
reference, the concentration of vector achieved with 1 3
1013 vg was 2.2 3 1014 vg/kg, 1-log-fold higher than the
1.63 1013 vg/kgdosegiven to the late-IUGT recipients (29,
33).At46gat IUGT, the injected fetus is assumed to contain
;5 3 1010 cells (65); at the median birth weight of 275 g
the total number of cells per infant is expected to reach
;3 3 1011 cells, over a mean of 60 d. Late-IUGT animals
grew 2–3-fold over the first 60 d of life (injections were
performed1wkbeforebirth).With1-log-foldhighervector
loadat early-IUGTto0.6-log-fold increase in cell numbers, it
is anticipated that, given the same efficacy of transduction,
early-IUGT recipients would have higher expression from
greater cellular transduction. We instead have observed
lower expression, and posit that gestation-sensitive differ-
ences in themetabolic stateofhepatocytesmaybe important
contributory factors (63). Possible saturation kinetics were
seen with AAV5-hFIX and AAV5-hFX, as there was no
discernible improvement in transgenic protein production
with log-fold increases of vector. The reason remains un-
known, but we postulate that the early fetal liver is more
resistant to AAV5 transduction, perhaps because of cell
surface receptors or other dynamics of vector-cell interac-
tions. In addition, it is known that hFIX increases steadily in
childhood, whereas hFX levels are significantly lower at
birth, only reaching adult levels by 5 yr of age (66). Initially
low transgenic protein levels reflect hepatic functional im-
maturity at the time of AAV-GT and eventually rise to
clinically normal levels with age. The differences in indi-
vidual transgenic protein production fromAAV8 and -5
are not clinically relevant here, given that steady-state
expression of both transgenes reached therapeutic levels.
Immune responses to the primaryAAVdose remained
low, and the distinct immunogenicity of AAV5 observed
among immune-mature recipients (late-gestation fetuses
and adults) was absent in these early recipients (33, 59).
Although T-cell assays were not performed after early-
IUGT, sustained expression in most recipients supports
the absence of a primary cellular immune response. A
transient increase inALT inAAV5animalswasnotadirect
result of the postnatal challenge (occurring 4–6 mo after
VC), and this biochemical observation did not coincide
with loss of transgenic protein production in the surviving
AAV5-treated animals. Maternal IgG production was ob-
served during the first 12 mo with AAV5 demonstrating
greater immunogenicity than AAV8, consistent with our
prior observations in late-gestation IUGT (29, 33). AAV5-
injected dams had 1.5–1.8-fold higher anti-capsid and anti-
hFIX antibody levels compared to offspring (similar levels
with AAV8). It is possible that antibodies detected in off-
spring are transplacentally trafficked maternal antibodies,
which may have accounted for some of the humoral re-
sponse in treated infants. It is also possible that prolonged
low-level anti-AAV IgG in early recipients indicates amild
primary response in most animals. Transplacental mater-
nal immune influence on fetal expression has been de-
scribed inmurineexperiments (67, 68). Thedegree towhich
transgenic protein production is influenced by maternal
immunity is unknown; this may be a contributing factor
toward low expression andwarrants further investigation.
Post-VC responses in 0.4 gestation animals (compared
to 0.9 gestation) demonstrated similar transgenic protein
production, lower anti-AAV IgG production (remaining
well below the positive limit), transientNAb expression in
1 of 3 challenged animals vs. NAb following all 3 chal-
lenges after late-IUGT, and a higher percentage of acti-
vated T cells expressing intracellular cytokines (33). Early
Figure 6. Vector biodistribution and hepatotoxicity. A) VCNs
showed wide variation with most subjects expressing 1 vector
copy every 10–1000 cells in the absence of speciﬁc organ
tropism. B) Regardless of initial VCN, all tissues showed a
substantial decline in tissue vector load of 1–3-log-fold every 12
mo; there was no difference between AAV5- and AAV8-treated
animals. C) Liver-speciﬁc ALT levels increased intermittently,
particularly in AAV8 recipients, but overall transaminases
remained in the normal range.
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NAb and activated T-cell productionmay have prevented
transduction in e5002FX via immune-mediated clearance
of transduced cells or prevention of vector entry. Recovery
of expression in e5002 and e5002FX could be attributed to
the eventual loss of T cells and NAb. Given this immune
reaction, even the brief appearance of NAb can influence
the outcomes of postnatal boosting.Although it is generally
believed that early-gestation fetuses are immune naive, our
data suggest that theyarecapableof immuneresponsesand
retain partial ability to eliminate transduced hepatocytes.
Despite this, sustained transgenic protein production dur-
ing this period suggests a certain degree of peripheral tol-
erance that facilitates postnatal boosting. A higher VCdose
may overcome this barrier and remains to be tested.
Our data revealed no adverse events derived from di-
rect AAV toxicity or insertional mutagenesis during the
4-yr surveillance in contrast to recent studies thatused log-
fold higher doses (49, 69). The sustained high transgenic
protein productionwith rapidlydecreasingVCNsuggests
that long-term transgene production derives from in-
tegrated vectormore than from concatemers, althoughwe
did not demonstrate this with certainty; we also did not
observe evidence of liver cancer.
The number of animals with long-term follow-up was
small,ultimately limiting thepowerof importantconclusions
regarding durability of expression and immune re-
sponse. Pregnancy losses were expected, given the high
incidence among captive-bred NHPs (29, 50). There was
no increase in postnatal mortality compared with our
late-IUGT cohort apart from procedure-related deaths
and nosocomial infections. The ratio of females to males
was higher in the AAV5 group, but lower in the AAV8
group, and this would have influenced transgenic pro-
tein production readouts to some extent, given the in-
fluence of gender, as we have previously described (33).
We did not determine the dose-response to AAV5-FIX
Figure 7. Vector ISs. A) Integration frequency increased from 40 to 70% at 10 mo to .80% at 42 mo in the different animals
sampled. B) No differences in integration frequencies were noted between AAV5 and -8. C–E) Relative sequence counts of the 10
most prominent IS retrieved were calculated in relation to all uniquely mappable IS sequences in e8001 at 10 mo (C), e8003 at 10
mo (D, E), and e5002 at 19 mo (after VC). The RefSeq identities of the gene located adjacent to or at the IS are listed.
TABLE 2. Vector ISs retrieved from liver biopsies
Animal ID Gender
Months
after birth Raw reads
IS
reads
Total
IS
Unique
IS
Multiple
IS
IS/mg
DNA
e5002 Female 19a 1,192,771 4 4 4 4 5.33
e5005 Male 42 194,372 7 1 - 1 1.33
e8001 Male 10 1,077,767 262 99 96 3 132
e8003 Male 10 1,752,537 28 17 11 6 22.67
Multiple IS, multiple mappable ISs; unique IS, uniquely mappable ISs. aAnimal subjected to post-
natal VC 16 mo after birth.
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because of experimental constraints imposed by the real-
time availability of pregnant animals. The fetuses of
AAV5-seronegative mothers were the first to be treated
when there was a primary need to establish procedural
safety. The initial lower dose of 1 3 1012 vg/fetus was
based on previous studies that determined the effective
dose of this vector in mice and adult macaques suffi-
cient to achieve therapeutic expression (44, 70). The ad-
ministered dose was further constrained by the volume
limitation imposed by fetal size and was deliberately
kept low to avoid circulatory embarrassment. Fetuses
were subsequently treated with a higher dose of AAV8-
hFIX when the suboptimal therapeutic achievements of
AAV5-hFIX recipients became evident. We performed
ICS for cytokines in activated T cells rather than enzyme-
linked immunospot (ELISPOT). We chose this method
because of the advantage of simultaneous assessment of
multiple surface markers and effector cytokines reflect-
ing the phenotype and function of reactive T cells. Al-
though there are advantages to ELISPOT, we preferred
the range and quantitative readouts of flow cytometry
(71). Although the method may be nonstandard com-
pared to ELISPOT, there is a growing number of studies
applying ICS as the method of choice because of the
greater flexibility and breadth of this assay. In NAb as-
says we did not perform serial dilutions, and although
these semiquantitative assays suggest that high titers of
NAbwere not present,we cannot exclude thepresence of
low NAb titers in these samples.
In summary, early-IUGT can make a critical contribu-
tion in the therapeutic arsenal for congenital diseases that
produce pathology in early development that may other-
wise result in fetal loss or severe permanent handicap.
Within the parameters of this research, we have demon-
strated its usefulness in achieving curative levels of
transgenic protein. Compared with late-IUGT, potential
benefits extend from correction of early fetal pathogenesis
to a higher degree of immune tolerance to postnatal repeat
treatment to boost suboptimal outcomes. It can be inter-
preted from this study that serotype, dose, production of
NAb and a stimulated T-cell response are factors critical to
a long-term approach. Further immune modulation may
still be necessary, as practiced in recent AAV clinical trials
(3, 4, 72). No adverse effects of AAV toxicity or integration
were observed during 4 yr of surveillance. Long-term
therapeutic expression relies significantly on an integrated
vector. Individual therapeutic strategies should be opti-
mized further in the NHP model to assess translational
potential.
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